Comparison between drug-eluting bead transarterial chemoembolization versus conventional TACE in elderly patients with colorectal cancer liver metastases: a cohort study - Report - MDSpire
Advertisement
Comparison between drug-eluting bead transarterial chemoembolization versus conventional TACE in elderly patients with colorectal cancer liver metastases: a cohort study
Clinical Report: Evaluation of DEB-TACE vs Conventional TACE in Elderly CRCLM Patients
Overview
This study compares the efficacy and safety of drug-eluting bead transarterial chemoembolization (DEB-TACE) with conventional TACE (cTACE) in elderly patients with colorectal cancer liver metastases (CRCLM). DEB-TACE demonstrated a longer progression-free survival compared to cTACE, although overall survival differences were not statistically significant.
Background
Colorectal cancer is a leading cause of cancer-related mortality, with liver metastases significantly impacting patient outcomes. Traditional treatment options for elderly patients with unresectable CRCLM are limited, making effective regional therapies like TACE crucial. DEB-TACE offers potential advantages over cTACE, including higher intratumor drug concentrations and reduced systemic toxicity, warranting further investigation in this demographic.
Data Highlights
Outcome
DEB-TACE
cTACE
P-value
Complete Response Rate
10.0%
4.3%
0.468
Objective Response Rate
55.0%
30.4%
0.103
Disease Control Rate
95.0%
82.6%
0.206
Progression-Free Survival (months)
11.7
6.1
0.013
Overall Survival (months)
21.6
16.3
0.076
Key Findings
DEB-TACE showed a median progression-free survival of 11.7 months compared to 6.1 months for cTACE (P = 0.013).
The complete response rate was 10.0% for DEB-TACE versus 4.3% for cTACE (P = 0.468).
The objective response rate was higher in the DEB-TACE group at 55.0% compared to 30.4% in the cTACE group (P = 0.103).
No significant differences in adverse events were noted between DEB-TACE and cTACE.
Overall survival showed a trend favoring DEB-TACE with 21.6 months compared to 16.3 months for cTACE (P = 0.076).
Clinical Implications
DEB-TACE may be a viable treatment option for elderly patients with unresectable CRCLM, potentially offering improved progression-free survival without increased adverse events compared to cTACE. Clinicians should consider patient-specific factors when selecting between DEB-TACE and cTACE.
Conclusion
DEB-TACE presents a promising alternative to cTACE in treating elderly patients with CRCLM, particularly in terms of progression-free survival. Further studies are needed to confirm these findings and establish definitive treatment protocols.
